- 產(chǎn)品描述
美國(guó)Seracare衣原體IgG(Chlamydia IgG)
廣州健侖生物科技有限公司
廣州健侖長(zhǎng)期供應(yīng)各種生物原料,主要代理品牌:美國(guó)Seracare、西班牙Certest、美國(guó)Fuller等等。
主要產(chǎn)品包括各種標(biāo)準(zhǔn)品、陽(yáng)性對(duì)照品、單克隆抗原抗體。
其中常見(jiàn)的有:弓形蟲(chóng)病、西尼羅河病毒、類風(fēng)濕因子、瘧疾、麻疹、萊姆病、百日咳桿菌、大腸桿菌、鼠傷寒沙門氏菌、李斯特菌等陽(yáng)性對(duì)照品。
美國(guó)Seracare衣原體IgG(Chlamydia IgG)
我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢
歡迎咨詢2042552662
【Seracare產(chǎn)品介紹】
編號(hào) | 英文名稱 | 中文名稱 |
JL-FA-01 | Amebiasis (AME) | 阿米巴病 |
JL-FA-02 | Allergens, Rast scores | 過(guò)敏原,放射性過(guò)敏原吸收實(shí)驗(yàn)。指對(duì)特定的人群引起免疫反應(yīng)或者過(guò)敏反應(yīng)的食品中的蛋白質(zhì) |
JL-FA-03 | Allergens, Rast scores negative | 過(guò)敏原,放射性過(guò)敏原吸收實(shí)驗(yàn)陰性 |
JL-FA-04 | Anti-cyclic citrullinated peptide Antibody (CCP) Arthritis | 抗環(huán)瓜氨酸肽抗體 |
JL-FA-05 | ASCA Saccharomyces Cerevi | 人抗釀酒酵母抗體(ASCA) |
JL-FA-06 | Aspergillis | 麴菌病 |
JL-FA-07 | Beta 2 Glycoprotein | β2糖蛋白 |
JL-FA-08 | Beta 2 Glycoprotein IgM | β2糖蛋白 IGM |
JL-FA-09 | Bordela Pertussis | 百日咳桿菌 |
JL-FA-10 | Bordela Pertussis IgM | 百日咳桿菌 IGM |
JL-FA-11 | C-ANCA | C-抗中性粒細(xì)胞胞漿抗體(ANCA) |
JL-FA-12 | Cardiolipin | 心肌磷脂 |
JL-FA-13 | Cardiolipin IgA | 心肌磷脂 IGA |
JL-FA-14 | Cardiolipin IgG | 心肌磷脂 IGG |
JL-FA-15 | Cardiolipin IgM | 心肌磷脂 IGM |
JL-FA-16 | Cerebral Spinal Fluid | 腦脊髓液 |
JL-FA-17 | Chagas | 恰加斯病/南美錐蟲(chóng) |
JL-FA-18 | Chlamydia | 衣原體 |
JL-FA-19 | Chlamydia IgA | 衣原體IGA |
JL-FA-20 | Chlamydia IgG | 衣原體IGG |
JL-FA-21 | Chlamydia IgM | 衣原體IGM |
JL-FA-22 | Chlamydia Neg | 衣原體陰性 |
JL-FA-23 | Clotting Factor C3 | 凝固因子C3 |
JL-FA-24 | Clotting Factor C4 | 凝固因子C4 |
JL-FA-25 | Coccidiodes | 球孢菌 |
JL-FA-26 | Cytomegalovirus (CMV) Neg | 巨細(xì)胞病毒抗體陰性 |
JL-FA-27 | CMV IgG | 巨細(xì)胞病毒 IGG陽(yáng)性 |
JL-FA-28 | CMV IgM VCA | 巨細(xì)胞病毒 IGM 陽(yáng)性 |
JL-FA-29 | C-Reactive Protein (CRP) | C-反應(yīng)蛋白質(zhì) |
JL-FA-30 | Dengue Fever | 登革熱 |
JL-FA-31 | Dengue Fever IgM | 登革熱 IGM |
JL-FA-32 | DS (Double Stranded) DNA | 雙鏈脫氧核糖核酸 |
JL-FA-33 | EBNA (Epstein-Barr nuclear antigen) IgG | EB病毒核抗原 IGG |
JL-FA-34 | EBNA (Epstein-Barr nuclear antigen) IgM | EB病毒核抗原 IGM |
JL-FA-35 | Epstein Barr Virus (EBV) Negative Plasma | EB病毒陰性血漿 |
JL-FA-36 | Epstein Barr Virus (EBV) EA IgM | EB病毒早期抗原 IGM |
JL-FA-37 | Epstein Barr Virus (EBV) VCA IgM | EB病毒殼蛋白 IGM |
JL-FA-38 | Epstein Barr Virus (EBV) EA IgG | EB病毒早期抗原 IGG |
JL-FA-39 | EMA (Endomysial Antibodies) | 肌內(nèi)膜 |
JL-FA-40 | Gliadin | 麩蛋白,麥醇溶蛋白,麥膠蛋白 |
JL-FA-41 | Gliadin IgG | 麥醇溶蛋白 IGG |
JL-FA-42 | Gliadin IgA | 麥醇溶蛋白 IGA |
JL-FA-43 | Glomerular Basement Membrane (GBMA) | 腎小球基底膜病 |
JL-FA-44 | Helicobacter pylori IgA | 幽門螺旋桿菌IGA |
JL-FA-45 | Helicobacter pylori IgG | 幽門螺旋桿菌IGG |
JL-FA-46 | Helicobacter pylori IgM | 幽門螺旋桿菌IGM |
JL-FA-47 | Helicobacter pylori Negative | 幽門螺旋桿菌陰性 |
JL-FA-48 | Helicobacter pylori Positive Plasma | 幽門螺旋桿菌陰性血漿 |
JL-FA-49 | Hepatitis A Virus (HAV) Pos. Plasma | 甲型肝炎病毒陽(yáng)性血漿 |
JL-FA-50 | Hepatitis A Virus (HAV) IgM | 甲型肝炎病毒IGM |
JL-FA-51 | Hepatitis B Core (HBc) IgG | 乙型肝炎病毒核心 IGG |
JL-FA-52 | Hepatitis B Core (HBc) IgM | 乙型肝炎病毒核心 IGM |
JL-FA-53 | Anti Hbe (Antibody to HBV antigen) | 乙肝抗體 |
JL-FA-54 | Hepatitis Delta Virus | 丁型肝炎病毒 |
JL-FA-55 | HBeAg (HBV e antigen) | 乙肝 E抗原 |
JL-FA-56 | anti-HBs (HBV surface antibody) | 乙肝表面抗體 |
JL-FA-57 | Hepatitis B (HBsAg) "Chronic" | 乙型肝炎(乙肝表面抗原)“慢性病 |
JL-FA-58 | HBsAg (HBV surface antigen) Serum | 乙肝表面抗原血清 |
JL-FA-59 | HBsAg (AD) | 乙肝表面抗原(AD) |
JL-FA-60 | HBsAg (AY) | 乙肝表面抗原(AY) |
JL-FA-61 | HBV Positive Plasma | 乙肝陽(yáng)性血漿 |
JL-FA-62 | HBV DNA Plasma | 乙肝DNA血漿 |
JL-FA-63 | HBV DNA Serum | 乙肝DNA血清 |
JL-FA-64 | HBV DNA type A | A型 乙肝DNA |
JL-FA-65 | HBV DNA type B | B型 乙肝DNA |
JL-FA-66 | HBV DNA type C | C型 乙肝DNA |
JL-FA-67 | HBV DNA type D | D型 乙肝DNA |
JL-FA-68 | HBV DNA type E | E型 乙肝DNA |
JL-FA-69 | HBV DNA type F | F型 乙肝DNA |
JL-FA-70 | HBV Antibody HCV Antibody Plasma CO-INFECTED | 乙肝和丙肝聯(lián)合感染血漿 |
JL-FA-71 | HCV (Hepatitis C Virus) Antibody | 丙型肝炎抗體 |
JL-FA-72 | HCV Core Antigen Positive | 丙肝核心抗原 陽(yáng)性 |
JL-FA-73 | HCV RNA PLASMA Genotype 1 | 基因1型丙肝RNA 血漿 |
JL-FA-74 | HCV RNA PLASMA Genotype 2 | 基因2型丙肝RNA 血漿 |
JL-FA-75 | HCV RNA PLASMA Genotype 3 | 基因3型丙肝RNA 血漿 |
JL-FA-76 | HCV RNA PLASMA Genotype 4 | 基因4型丙肝RNA 血漿 |
JL-FA-77 | HCV RNA PLASMA Genotype 5 | 基因5型丙肝RNA 血漿 |
JL-FA-78 | HCV RNA PLASMA Genotype 6 | 基因6型丙肝RNA 血漿 |
JL-FA-79 | HCV Riba single band | 丙肝免疫印跡單波段 |
JL-FA-80 | HCV RIBA Pos. (multiple bands) | 丙肝免疫印跡陽(yáng)性多波段 |
JL-FA-81 | HCV Negative | 丙肝陰性 |
JL-FA-82 | HCV RNA Pos (quantitative) | 丙肝RNA陽(yáng)性(定量) |
JL-FA-83 | Hepatitis E | 戊型肝炎 |
JL-FA-84 | Herpes Simplex Virus (HSV)1/2 Positive Plasma | 單純性皰疹病毒1/2陽(yáng)性血漿 |
JL-FA-85 | Herpes Simplex Virus (HSV) 1 Negative Plasma | 單純性皰疹病毒1 陰性血漿 |
JL-FA-86 | Herpes Simplex Virus (HSV) 1 IgG | 單純性皰疹病毒1 IGG |
JL-FA-87 | Herpes Simplex Virus (HSV 1) IgM | 單純性皰疹病毒1 IGM |
JL-FA-88 | Herpes Simplex Virus (HSV) 2 IgG | 單純性皰疹病毒2 IGG |
JL-FA-89 | Herpes Simplex Virus (HSV) 2 IgM | 單純性皰疹病毒2 IGG |
JL-FA-90 | Histone | 組蛋白 |
JL-FA-91 | Human Anti Mouse Ab (HAMA) | 人抗鼠抗體 |
JL-FA-92 | Human immunodeficiency virus (HIV) 1 Neg | HIV I 陰性 |
JL-FA-93 | anti Human immunodeficiency virus (HIV) 1 Plasma | 抗HIV I 血漿 |
JL-FA-94 | anti Human immunodeficiency virus (HIV) 1 Serum | 抗HIV I 血清 |
JL-FA-95 | anti Human immunodeficiency virus (HIV) 2 Western Blot Tested | 抗HIV 2 免疫印跡 |
JL-FA-96 | anti Human immunodeficiency virus (HIV) 1/2 2 HIV (+) | 抗HIV 1/2 2 HIV陽(yáng)性 |
JL-FA-97 | Human immunodeficiency virus (HIV) Ag | HIV抗原 |
JL-FA-98 | HIV RNA (quantitative) Plasma | HIV RNA 定量血漿 |
JL-FA-99 | HIV RNA (quantitative) Serum | HIV RNA 定量血清 |
JL-FA-100 | HIV1 Subtype A | HIV1 亞型A |
JL-FA-101 | HIV1 Subtype B | HIV1 亞型B |
JL-FA-102 | HIV1 Subtype C | HIV1 亞型C |
JL-FA-103 | HIV1 Subtype D | HIV1 亞型D |
JL-FA-104 | HIV1 Subtype E | HIV1 亞型E |
JL-FA-105 | HIV1 Subtype F | HIV1 亞型F |
JL-FA-106 | HIV1 Subtype G | HIV1 亞型G |
JL-FA-107 | HIV1 Subtype H | HIV1 亞型H |
JL-FA-108 | HIV1 Subtype J | HIV1 亞型J |
JL-FA-109 | HIV1 Subtype K | HIV1 亞型K |
JL-FA-110 | HIV1 Group O | HIV1 亞型O |
JL-FA-111 | Human immunodeficiency virus (HIV) 2 Antibody Plasma | HIV 2 抗體血漿 |
JL-FA-112 | Human immunodeficiency virus (HIV) 2 Antibody Serum | HIV 2 抗體血清 |
JL-FA-113 | HPV (Human Papiloma Virus) Negative | 人乳狀瘤病毒HPV陰性 |
JL-FA-114 | HPV (Human Papiloma Virus) Positive | 人乳狀瘤病毒HPV陽(yáng)性 |
JL-FA-115 | Human immunodeficiency virus (HIV) Antibody HCV Antibody Plasma COINFECTED | HIV 抗體 HCV |
JL-FA-116 | Human T-cell Lymphotropic Virus (HTLV) I/II | 人嗜T淋巴細(xì)胞病毒(HTLV) I/II |
JL-FA-117 | Human T-cell Lymphotropic Virus (HTLV) I | 人嗜T淋巴細(xì)胞病毒(HTLV) I |
JL-FA-118 | Human T-cell Lymphotropic Virus (HTLV) II | 人嗜T淋巴細(xì)胞病毒(HTLV) II |
JL-FA-119 | Jo-1 | 多發(fā)性肌炎抗原JO-1 |
JL-FA-120 | IgE < 5,000 Ku/L | IgE < 5,000 Ku/L |
JL-FA-121 | Legionella | 軍團(tuán)桿菌屬 |
JL-FA-122 | Leptospira | 軍團(tuán)桿菌屬 |
JL-FA-123 | Lyme Disease | 萊姆(氏)病:蜱傳播的全身性疾病,常在夏季發(fā)生 |
JL-FA-124 | Lyme IgG | 萊姆(氏)病 IGG |
JL-FA-125 | Lyme IgM | 萊姆(氏)病 IGM |
JL-FA-126 | Lyme Disease Neg | 萊姆(氏)病 陰性 |
JL-FA-127 | Malaria | 瘧疾 |
JL-FA-128 | Mononucleosis (infectious) | 單核細(xì)胞增多癥(有傳染性的) |
JL-FA-129 | Mononucleosis Negative | 單核細(xì)胞增多癥陰性 |
JL-FA-130 | Measles Negative | 麻疹 陰性 |
JL-FA-131 | Measles IgG | 麻疹 IGG |
JL-FA-132 | Measles IgM | 麻疹 IGM |
JL-FA-133 | Microsomal Anti-thyroid peroxidase antibody (TPO) Positive Plasma Standard Titer (typically 1,000-3,000 IU/mL) | 微粒體抗甲狀腺過(guò)氧化物酶抗體 |
JL-FA-134 | Microsomal Anti-thyroid peroxidase antibody (TPO) Negative Plasma | 微粒體抗甲狀腺過(guò)氧化物酶抗體 |
JL-FA-135 | Anti-mitochondrial antibody (AMA) | 抗線粒體抗體 |
JL-FA-136 | Multiple Sclerosis | 多發(fā)性硬化癥 |
JL-FA-137 | Mumps IgG | 流行性腮腺炎 IGG |
JL-FA-138 | Mumps Ab IgM | 流行性腮腺炎抗體 IGM |
JL-FA-139 | Mumps Antibody Negative Plasma | 流行性腮腺炎抗體陰性血漿 |
JL-FA-140 | Mumps Antibody Negative Serum | 流行性腮腺炎抗體陰性血清 |
JL-FA-141 | Myeloma Plasma | 骨髓瘤血漿 |
JL-FA-142 | Myeloma IgA | 骨髓瘤IGA |
JL-FA-143 | Myeloma IgE | 骨髓瘤IGE |
JL-FA-144 | Myeloma IgG | 骨髓瘤IGG |
JL-FA-145 | Myeloma IgM | 骨髓瘤IGM |
JL-FA-146 | Mycoplasma | 支原體 |
JL-FA-147 | Mycoplasma Negative | 支原體陰性 |
JL-FA-148 | Mycoplasma IgG | 支原體IGG |
JL-FA-149 | Mycoplasma IgM | 支原體IGM |
JL-FA-150 | Mycoplasma PCR | 支原體PCR |
JL-FA-151 | Normal Human Plasma | 正常人血漿 |
JL-FA-152 | Normal Human Serum | 正常人血清 |
JL-FA-153 | Nuclear Antibody Centromere | 核抗體著絲粒 |
JL-FA-154 | Nuclear Antibody, Speckled ANA | 核抗體,斑點(diǎn)抗核抗體 |
JL-FA-155 | Nuclear Antibody, Nucleolar ANA | 核抗體,核仁抗核抗體 |
JL-FA-156 | Nuclear Antibody, Homogeneous ANA | 核抗體,同質(zhì)抗核抗體 |
JL-FA-157 | Nuclear Antiobody, Speckled. (ANA) Negative | 核抗體,斑點(diǎn)。抗核抗體陰性 |
JL-FA-158 | P-ANCA (associated neutrophil cytoplasmic antibodies) | 相關(guān)的嗜中性粒細(xì)胞胞漿抗體 |
JL-FA-159 | Parietal Cell Antibody (PCA) | 胃)壁細(xì)胞抗體 |
JL-FA-160 | Parvo positive plasma | 細(xì)小病毒陽(yáng)性血漿 |
JL-FA-161 | Parvo IgM | 細(xì)小病毒 IGM |
JL-FA-162 | Parvo IgG | 細(xì)小病毒 IGG |
JL-FA-163 | Parvo Negative Plasma | 細(xì)小病毒陰性血漿 |
JL-FA-164 | Parvo DNA positive | 細(xì)小病毒 DNA 陽(yáng)性 |
JL-FA-165 | Phospholipid Positive Plasma | 磷脂陽(yáng)性血漿 |
JL-FA-166 | Prothrombin | 凝血酶原,凝血因子 |
JL-FA-167 | Rheumatoid Factor (RF) <1000 IU/mL | 類風(fēng)濕因子<1000 IU/mL |
JL-FA-168 | Rheumatoid Factor (RF) 1001-2000 IU/mL | 類風(fēng)濕因子1001-2000 IU/mL |
JL-FA-169 | Rheumatoid Factor (RF) 2001-4000 IU/mL | 類風(fēng)濕因子 2001-4000 IU/mL |
JL-FA-170 | Rheumatoid Factor (RF) 4001-5000 IU/mL | 類風(fēng)濕因子 4001-5000 IU/mL |
JL-FA-171 | Rheumatoid Factor (RF) >5000 IU/mL | 類風(fēng)濕因子>5000 IU/mL |
JL-FA-172 | Ribonucleoprotein (RNP) Positive | 核糖核蛋白陽(yáng)性 |
JL-FA-173 | Rubella Chimeric | 風(fēng)疹 |
JL-FA-174 | Rubella Negative | 風(fēng)疹陰性 |
JL-FA-175 | Rubella IgG | 風(fēng)疹I(lǐng)GG |
JL-FA-176 | Rubella IgM | 風(fēng)疹I(lǐng)GM |
JL-FA-177 | Rubeola Negative Plasma | 風(fēng)疹陰性血漿 |
JL-FA-178 | Rubeola IgG | 風(fēng)疹I(lǐng)GG |
JL-FA-179 | Scleroderma (Scl-70) Pos | 膠原沉著病,硬皮病,硬皮癥 陽(yáng)性 |
JL-FA-180 | Scleroderma (Scl-70) Negative | 硬皮病陰性 |
JL-FA-181 | Sickle Cell Fresh Whole Blood | 鐮刀形紅細(xì)胞新鮮全血 |
JL-FA-182 | Smith (SM) | 抗Smith抗體陽(yáng)性血清(SLE的特征性抗體) |
JL-FA-183 | SMITH RNP | 抗RNP抗體陽(yáng)性血清(SLE的特征性抗體) |
JL-FA-184 | Smooth Muscle (ASMA) | 抗平滑肌抗體陽(yáng)性血清 |
JL-FA-185 | Sjogren syndrome antigen A (SSA) Positive | 舍格倫綜合征或干燥綜合征抗原A 陽(yáng)性 |
JL-FA-186 | Sjogren syndrome antigen B (SSB) Positive | 舍格倫綜合征抗原B 陽(yáng)性 |
JL-FA-187 | Sjogren syndrome antigen B (SSB) Negative | 舍格倫綜合征抗原B陰性 |
JL-FA-188 | Streptolysin O Ab (ASO) | 鏈球菌溶血素O抗體 |
JL-FA-189 | Syphilis (RPR - Rapid Plasma Reagin) Positive Plasma | 梅毒(梅毒-快速血漿反應(yīng))陽(yáng)性血漿 |
JL-FA-190 | Syphilis (RPR - Rapid Plasma Reagin) Negative Plasma | 梅毒(梅毒-快速血漿反應(yīng))陰性血漿 |
JL-FA-191 | Syphilis/ATA/T. pallidum IgG | 梅毒ATA/T,蒼白球IGG |
JL-FA-192 | Syphilis/ATA/T. pallidum IgM | 梅毒ATA/T,蒼白球IGM |
JL-FA-193 | Systemic Lupus Erythematosus (SLE) Positive | 全身性紅斑狼瘡陽(yáng)性 |
JL-FA-194 | Systemic Lupus Erythematosus (SLE) Negative | 全身性紅斑狼瘡陰性 |
JL-FA-195 | TG/TPO Positive (Standard Titer 1,000 - 3000 IU/mL) | 甲狀腺球蛋白/甲狀腺過(guò)氧化物酶陽(yáng)性 |
JL-FA-196 | TG/TPO Negative | 甲狀腺球蛋白/甲狀腺過(guò)氧化物酶陰性 |
JL-FA-197 | TTG (Tissue Transglutaminase) | 組織轉(zhuǎn)谷氨酰胺酶 |
JL-FA-198 | TTG (Tissue Transglutaminase) IgA | 組織轉(zhuǎn)谷氨酰胺酶 IGA |
JL-FA-199 | ToRCH (Toxo, Rubella, CMV, HSV) Positive | 優(yōu)生優(yōu)育(弓形蟲(chóng),風(fēng)疹,巨細(xì)胞,單胞)陽(yáng)性 |
JL-FA-200 | ToRCH (Toxo, Rubella, CMV, HSV) Negative | 優(yōu)生優(yōu)育(弓形蟲(chóng),風(fēng)疹,巨細(xì)胞,單胞)陰性 |
JL-FA-201 | Toxoplasmosis (Toxo) | 弓形蟲(chóng)病 |
JL-FA-202 | Toxoplasmosis (Toxo) IgG | 弓形蟲(chóng)病IGG |
JL-FA-203 | Toxoplasmosis (Toxo) IgM | 弓形蟲(chóng)病IGM |
JL-FA-204 | Thyroglobulin (TG) Positive Plasma | 甲狀腺球蛋白陽(yáng)性血漿 |
JL-FA-205 | Thyroglobulin (TG) Negative | 甲狀腺球蛋白陰性 |
JL-FA-206 | Varicella-Zoster Virus (VZV) Negative | 水痘-帶狀皰疹病毒陰性 |
JL-FA-207 | Varicella-Zoster Virus (VZV) IgG | 水痘-帶狀皰疹病毒IGG |
JL-FA-208 | Varicella-Zoster Virus (VZV) IgM | 水痘-帶狀皰疹病毒IGM |
JL-FA-209 | West Nile Virus (WNV) | 西尼羅河腦炎病毒 |
JL-FA-210 | West Nile Virus (WNV) IgM | 西尼羅河腦炎病毒IGM |
美國(guó)
美國(guó)斯隆-凱特琳研究所等處的研究人員創(chuàng)建了一種多能干細(xì)胞基因組編輯平臺(tái):iCRISPR,這一平臺(tái)能快速,高效的敲除干細(xì)胞中的基因,而且還能在干細(xì)胞分化過(guò)程中,進(jìn)行階段特異性的基因敲除,這將在人類疾病復(fù)雜病理研究中大放異彩。相關(guān)文章發(fā)表于2014年6月12日的《Cell Stem Cell》雜志上。
人體多能干細(xì)胞(hPSCs)不僅能被用于臨床的再生研究應(yīng)用中,而且也能作為解析復(fù)雜性狀和特征的*平臺(tái),闡明其背后的基因和分子途徑。為了實(shí)現(xiàn)這一目的,科學(xué)家們開(kāi)發(fā)了多種遺傳操控方法,但是這些方法依然存在各種問(wèn)題,我們需要快速,具有可操控性的生物學(xué)手段。
在這篇文章中,研究人員就利用CRISPR和TALEN,這兩種備受關(guān)注的基因組編輯技術(shù),研發(fā)出了一種人類多能干細(xì)胞基因組編輯平臺(tái)。研究人員將這一平臺(tái)稱為iCRISPR。
iCRISPR能用于基因功能喪失研究中,快速,高效的敲除人體多能干細(xì)胞中的等位基因,也可以針對(duì)一些精確的疾病模型,通過(guò)特定的核苷酸變換,進(jìn)行多能干細(xì)胞純合體敲除。
通過(guò)進(jìn)一步實(shí)驗(yàn),研究人員驗(yàn)證了雙重和三重基因敲除hPSC細(xì)胞系一步法的有效性,同時(shí)也證明了在多能干細(xì)胞分化過(guò)程中能進(jìn)行階段特異性誘導(dǎo)基因敲除,這對(duì)于發(fā)育生物學(xué)研究來(lái)說(shuō)意義重大。
由此研究人員指出,iCRISPR平臺(tái)尤其適合用于解析人類疾病研究中的復(fù)雜遺傳相互作用,以及多效性基因功能,這將有助于進(jìn)行人體多能干細(xì)胞高通量遺傳分析。
除了這項(xiàng)研究之外,去年來(lái)自加州大學(xué)舊金山分校的研究人員提出了一個(gè)相似的名稱:CRISPRi,他們發(fā)現(xiàn)當(dāng)缺失核酸內(nèi)切酶活性的Cas9與一種導(dǎo)向RNA共表達(dá)時(shí)候,會(huì)產(chǎn)生一種DNA識(shí)別復(fù)合物,這種復(fù)合物能特異性干擾轉(zhuǎn)錄延伸,RNA聚合酶結(jié)合,或轉(zhuǎn)錄因子結(jié)合。
由此研究人員研發(fā)出了這種CRISPRi系統(tǒng),這一系統(tǒng)能有效抑制大腸桿菌中靶向基因的表達(dá),并且不會(huì)出現(xiàn)脫靶效應(yīng)。而且利用CRISPRi,還可以同時(shí)抑制多個(gè)靶基因,這種作用也是可逆。研究人員還證明,該系統(tǒng)也適用于哺乳動(dòng)物細(xì)胞中的基因表達(dá)抑制。
加州大學(xué)圣迭戈分校(University of California, San Diego)醫(yī)學(xué)院研究人員針對(duì)自閉癥研究出一套比較新銳的理論,并對(duì)其進(jìn)行了實(shí)際測(cè)試。研究結(jié)果顯示,自閉癥實(shí)際上是由異常的細(xì)胞通訊導(dǎo)致的,使用問(wèn)世已逾百年的治療嗜睡癥的藥物,可以恢復(fù)患有自閉癥的老鼠體內(nèi)的細(xì)胞活動(dòng),消除老鼠的神經(jīng)失調(diào)癥狀。參與實(shí)驗(yàn)的老鼠年齡相當(dāng)于人類30歲左右。相關(guān)研究成果在2014年6月17日的在線刊物《平移精神病學(xué)(Translational Psychiatry)》中發(fā)表。
美國(guó)Seracare衣原體IgA(Chlamydia IgA)
我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】
Researchers at the U.S.-based Sloan-Caitlin Institute have created iCRISPR, a pluripotent stem cell genomics editing platform that rapidly and efficiently knocks out genes in stem cells and helps them differentiate stem cells during stem cell differentiation, Performing stage-specific knockouts will shine in the complex pathology of human disease. The article appeared in the June 12, 2014 issue of Cell Stem Cell.
Not only can human pluripotent stem cells (hPSCs) be used in clinical regenerative research applications, but also as a unique platform for analyzing complex traits and traits, elucidating the underlying genetic and molecular pathways. To achieve this goal, scientists have developed a variety of genetic manipulation methods, but there are still a variety of problems with these methods, and we need fast, manipulative biological tools.
In this article, researchers developed a human pluripotent stem cell genome editing platform using two well-regarded genome editing technologies, CRISPR and TALEN. The researchers call this platform iCRISPR.
iCRISPR can be used in gene loss studies to rapidly and efficiently knock out alleles in pluripotent human pluripotent stem cells and to target specific models of disease through specific nucleotide transforms for pluripotent stem cell homozygous knocking except.
Through further experiments, the researchers validated the one-step efficacy of double and triple knockout hPSC cell lines, and also demonstrated that stage-specific induction of gene knockdown during pluripotent stem cell differentiation can be performed in developmental biology Meaningful.
As a result, the researchers noted that the iCRISPR platform is particularly well-suited for the analysis of complex genetic interactions in human disease research and pleiotropic gene functions that will facilitate high-throughput genetic analysis of human pluripotent stem cells.
In addition to the study, researchers from the University of California, San Francisco, last year proposed a similar name: CRISPRi, who found that a DNA lacking endonuclease co-expressed with a directing RNA produced a DNA Recognition complexes that specifically interfere with transcriptional elongation, RNA polymerase binding, or transcription factor binding.
As a result, the researchers developed the CRISPRi system, which effectively inhibits the expression of the targeted genes in E. coli and does not show off-target effects. And using CRISPRi, you can also inhibit multiple target genes, this effect is also reversible. The researchers also demonstrated that the system is also suitable for gene expression inhibition in mammalian cells.
Researchers at the University of California, San Diego Medical School developed a set of cutting-edge theories of autism and conducted practical tests. The results show that autism is actually caused by abnormal cell communication, the use of more than a century has come out of the treatment of narcolepsy drugs, can restore autism in mice with cell activity in vivo, to eliminate symptoms of neurological disorders in mice . The age of the mice involved in the experiment is about 30 years old. Relevant research results are published in the June 17, 2014 online translation "Translational Psychiatry."